Drug Trial Radar · NCT07813039
A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
Sep 23, 2026
Primary completion
Oct 27, 2026
Study completion Oct 27, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the relative bioavailability of VX-581 tablet formulation compared to a suspension formulation along with its safety and tolerability.
Conditions
- Cystic Fibrosis
Interventions
VX-581Drug
Tablet and Suspension for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of VX-581Time frame: Period 1 and Period 2: From Day 1 up to Day 21
- Area Under the Concentration Versus Time Curve (AUC) of VX-581Time frame: Period 1 and Period 2: From Day 1 up to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion - Tempe
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.